What Rivus Pharmaceuticals does

Rivus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing Controlled Metabolic Accelerators (CMAs), a class of oral small-molecule therapeutics that act by inducing controlled mitochondrial uncoupling to improve cellular metabolism. The company's lead candidate, HU6, is being advanced in parallel Phase 2/3 and Phase 2b programs for metabolic dysfunction-associated steatohepatitis (MASH, including the AMPLIFY and M-ACCEL trials), with earlier-stage work in heart failure with preserved ejection fraction (HFpEF, HuMAIN trial) and Type 2 diabetes. Across these programs, HU6 has demonstrated 30–40% liver fat reduction, meaningful body weight reductions (approximately 6 lbs at higher doses, approximately 10 lbs in patients with elevated HbA1c), and has now been administered to more than 500 patients, with results published in Lancet Gastroenterology & Hepatology, JAMA Cardiology, and the European Journal of Heart Failure.

The company is broadening its pipeline through RV-8451, an oral non-peptide GLP-1 receptor agonist in IND-enabling preclinical development with a targeted IND submission in Q1 2027, positioning Rivus within the high-value oral incretin category. The company is headquartered in Charlottesville, Virginia, with a second operational site opened in South San Francisco in April 2025, and operates with a headcount of approximately 11–50 employees under a leadership team drawn from Vertex Pharmaceuticals, Genentech/Roche, Aimmune, J&J, GSK, and other major biopharma organizations.

As a pre-revenue, venture-backed private company, Rivus generates no commercial revenue and operates on equity capital, with cumulative disclosed financing of approximately $290M across a 2021 Series A ($35M), 2022 Series B ($132M, led by RA Capital with Bain Capital Life Sciences and BB Biotech AG), and subsequent 2024 and 2025 rounds totaling roughly $123M. Future revenue mechanics will depend on either direct commercialization of an approved CMA product, partnership/out-licensing arrangements, or both, though no commercial deals have been disclosed. The company targets large cardiometabolic markets — obesity affects approximately 1 billion individuals globally and MASH affects more than 5% of the U.S. adult population — offering substantial long-term commercial upside if clinical and regulatory milestones are achieved.

Name

Rivus Pharmaceuticals

Legal name

Rivus Pharmaceuticals, Inc.

Website

https://rivuspharma.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral small-molecule Controlled Metabolic Accelerators (CMAs) that leverage mitochondrial uncoupling to treat cardiometabolic diseases, with lead candidate HU6 in Phase 2/3 for MASH and HFpEF.

Ownership category

akta.pro rank

Product category

Cardiometabolic Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Cardiometabolic therapeutics
• Mitochondrial uncoupling drugs
• MASH oral therapy
• Obesity small molecule
• HFpEF treatment

Headquarters

HQ city

Charlottesville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral medicines for cardiometabolic diseases. The company is focused on advancing HU6 in Phase 2/3 clinical trials for MASH and HFpEF, with plans to commercialize its therapies upon regulatory approval. Revenue will be generated through product sales upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral small molecule medicines for cardiometabolic diseases based on its proprietary Controlled Metabolic Accelerators (CMAs) platform. Its lead candidate, HU6, is an oral once-daily CMA that increases energy expenditure through mitochondrial uncoupling to deliver fat-selective weight loss while preserving muscle mass, currently advancing in Phase 2 trials for MASH, HFpEF, and Type 2 diabetes/obesity. The pipeline also includes RV-8451, the industry's first muscle-preserving oral GLP-1 non-peptide agonist in IND-enabling studies for obesity.

Product overview

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of oral medicines for cardiometabolic diseases. The core technology platform is Controlled Metabolic Accelerators (CMAs), a new class of small molecule therapeutics that increase energy expenditure through mitochondrial uncoupling. The lead product is HU6, an oral therapy advancing in Phase 2 trials for MASH (AMPLIFY trial) and previously studied in HFpEF (HuMAIN trial) and obesity/MASLD. The pipeline also includes RV-8451, an oral GLP-1 non-peptide agonist in IND-enabling studies for obesity. Both products are designed to deliver fat-selective weight loss while preserving muscle mass, addressing key limitations of existing GLP-1 therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• HU6 HU6 is Rivus Pharmaceuticals' lead clinical-stage drug candidate — an oral, once-daily small molecule Controlled Metabolic Accelerator (CMA) that increases energy expenditure through mitochondrial uncoupling to promote fat-selective weight loss while preserving muscle mass. It is being developed for MASH (in the Phase 2 AMPLIFY trial), HFpEF (in the HuMAIN Phase 2a trial), Type 2 diabetes with obesity at risk of MASH (in the Phase 2b M-ACCEL trial), and obesity, with over 500 patients treated across Phase 2 trials.
• RV-8451 RV-8451 is described as the industry's first muscle-preserving oral GLP-1 non-peptide agonist — a highly differentiated oral GLP-1 therapy designed to deliver fat-specific, durable weight loss with convenient oral dosing for the treatment of obesity. It is currently in IND-enabling studies with planned IND submission targeted for Q1 2027.

Quantifiable outcome

• Liver fat reduction of 30-40% across doses in Phase 2a trials (p<0.0001)
• +5 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Eli Lilly: Eli Lilly is the dominant incumbent in cardiometabolic disease with Zepbound/Mounjaro (tirzepatide), and is advancing orforglipron (oral GLP-1) and other assets in obesity, MASH, and HFpEF. It sets the competitive benchmark Rivus must beat on efficacy, dosing convenience, and commercial reach.
• Novo Nordisk: Novo Nordisk is the GLP-1 category creator (Ozempic, Wegovy) and is actively expanding into MASH, HFpEF, and other cardiometabolic indications. Its commercial infrastructure and pipeline breadth define the realistic competitive ceiling for Rivus.

Direct peers

• Viking Therapeutics: Viking is advancing oral and injectable therapies for obesity and MASH, including VK2735 (GLP-1/GIP) and an oral formulation. It is a direct competitor to Rivus's HU6 and RV-8451 in the obesity/MASH overlap.
• Akero Therapeutics: Akero is developing efruxifermin (FGF21 analog) for MASH, a competing mechanism to Rivus's mitochondrial uncoupling. Both are clinical-stage companies targeting the same high-prevalence liver disease with disease-modifying claims.
• Structure Therapeutics: Structure Therapeutics is developing oral small molecules targeting GLP-1R for obesity and related cardiometabolic indications, directly comparable to Rivus's oral RV-8451 GLP-1 non-peptide agonist program.
• Inventiva: Inventiva is developing lanifibranor, an oral pan-PPAR agonist for MASH. It is a clinical-stage peer competing for the same oral MASH market with a differentiated but overlapping mechanism.
• 89bio: 89bio is developing pegozafermin for MASH, another direct competitor in the cardiometabolic liver disease space. Like Rivus, it is a clinical-stage biotech pursuing fibrosis improvement in MASH patients.
• Madrigal Pharmaceuticals: Madrigal developed Rezdiffra, the first FDA-approved oral therapy for MASH. It is the closest direct competitor to Rivus in the oral MASH space and a benchmark for clinical, regulatory, and commercial execution in this indication.

Emerging players

• Terns Pharmaceuticals: Terns is developing oral small molecule therapies for obesity and MASH, including TERN-501 (THR-β agonist) and an oral GLP-1. It is an emerging peer pursuing oral, muscle-friendly weight loss and liver-disease indications.
• Altimmune: Altimmune is developing pemvidutide, a GLP-1/glucagon dual agonist for obesity and MASH. It is a clinical-stage peer focused on the same cardiometabolic indications, with a different but overlapping mechanism.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rivuspharma
• LinkedInlinkedin.com/company/rivus-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rivus Pharmaceuticals